430 related articles for article (PubMed ID: 10944130)
1. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
Motzer RJ; Schwartz L; Law TM; Murphy BA; Hoffman AD; Albino AP; Vlamis V; Nanus DM
J Clin Oncol; 1995 Aug; 13(8):1950-7. PubMed ID: 7636535
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.
Pyrhönen S; Salminen E; Ruutu M; Lehtonen T; Nurmi M; Tammela T; Juusela H; Rintala E; Hietanen P; Kellokumpu-Lehtinen PL
J Clin Oncol; 1999 Sep; 17(9):2859-67. PubMed ID: 10561363
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer.
Jacobs A; Gold P; Weiden P; Aboulafia D; Rudolph R; Picozzi V; Thompson J
Cancer Invest; 2000; 18(5):417-21. PubMed ID: 10834025
[TBL] [Abstract][Full Text] [Related]
6. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
[TBL] [Abstract][Full Text] [Related]
9. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.
Escudier B; Chevreau C; Lasset C; Douillard JY; Ravaud A; Fabbro M; Caty A; Rossi JF; Viens P; Bergerat JP; Savary J; Négrier S
J Clin Oncol; 1999 Jul; 17(7):2039-43. PubMed ID: 10561255
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
[TBL] [Abstract][Full Text] [Related]
11. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma.
Jaremtchuk AV; Aman EF; Ponce W; Zarbá JJ; Ferro AM; Alvarez R; Vigo SA
Am J Clin Oncol; 2002 Apr; 25(2):123-5. PubMed ID: 11943887
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Vaishampayan U; Flaherty L; Du W; Hussain M
Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
[TBL] [Abstract][Full Text] [Related]
13. Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma.
Wong M; Goldstein D; Woo H; Testa G; Gurney H
Intern Med J; 2002 Apr; 32(4):158-62. PubMed ID: 11951927
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
17. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
19. Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis.
Roigas J; Deger S; Taymoorian K; Wille AH; Johannsen M; Türk I; Schnorr D; Loening SA
Cancer Biother Radiopharm; 2003 Apr; 18(2):157-63. PubMed ID: 12804041
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]